Publications by authors named "David James Pinato"

Claim this Profile
E
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.
Giuseppe Cabibbo, Ciro Celsa, Sherrie Bhoori, Thomas Reiberger, David James Pinato

J Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular carcinoma in people living with HIV.
Claudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, David James Pinato

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Ciro Celsa, Gabriele Di Maria, Pasquale Lombardi, Antonio D'Alessio, Claudia A M Fulgenzi, David James Pinato

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinoma.
Ciro Celsa, David James Pinato, Giuseppe Cabibbo

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers.
Giuseppe Cabibbo, Lorenza Rimassa, Angela Lamarca, Gianluca Masi, Bruno Daniele, David James Pinato

Cancer Treat Rev· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.
Ezequiel Mauro, Manuel Rodríguez-Perálvarez, Antonio D'Alessio, Gonzalo Crespo, Federico Piñero, David James Pinato

Liver Int· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Jaekyung Cheon, David James Pinato

J Hepatocell Carcinoma· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, Salvatore Battaglia, Marco Enea, David James Pinato

Hepatology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato

Viruses· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, Aman Mehan, Giulia F Manfredi, David James Pinato

JAMA Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "irLI or not irLI: That is the question".
Ciro Celsa, Giuseppe Cabibbo, David James Pinato

J Hepatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Ciro Celsa, Giuseppe Cabibbo, David James Pinato, Gabriele Di Maria, Marco Enea

Liver Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela S Allende, David James Pinato

Lancet Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.
Giulia Francesca Manfredi, Ciro Celsa, Chloe John, Charlotte Jones, Nicole Acuti, David James Pinato

J Hepatocell Carcinoma· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, Tomi Jun, Thomas U Marron, David James Pinato

World J Gastrointest Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Carlo Cattrini, Marcello Manfredi, Paola Barboro, Marco Ghirimoldi, Alessia Mennitto, David James Pinato

Sci Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis.
Georg Semmler, Bernhard Scheiner, Lorenz Balcar, Rafael Paternostro, Benedikt Simbrunner, David James Pinato

Aliment Pharmacol Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, David James Pinato

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study.
Mattia Bellan, Daria Apostolo, Alice Albè, Martina Crevola, Nicolò Errica, David James Pinato

Front Immunol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
Antonella Cammarota, Valentina Zanuso, Giulia Francesca Manfredi, Ravindhi Murphy, David James Pinato

Ther Adv Med Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, Naoshi Nishida, Celina Ang, David James Pinato

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre.
Maria J Monroy-Iglesias, Kathryn Tremble, Beth Russell, Charlotte Moss, Saoirse Dolly, David James Pinato

Future Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, David James Pinato

Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, David James Pinato

Hepatol Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Olabisi Ogunbiyi, Coskun O Demirtas, Alessandra Gennari, David James Pinato

Expert Opin Investig Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis